The development of next-generation sequencing has enabled the identification of a wider range of pathogenic germline mutations that increase the carriers’ risk of being diagnosed with pancreatic cancer, including ATM, BRCA1, BRCA2, MLH1, MSH2, MSH6, TP53, PALB2, PMS2, PRSS1, STK11, and CDKN2A [12,22]. Here, TP53 is linked to familial pancreatic carcinoma.